Scinai posts H1 net profit on $6.4 million bargain-purchase gain, offsetting wider CDMO gross loss

Reuters2026/08/26 12:14

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

For the six months ended June 30, 2026, revenue rose to USD 0.9 million from USD 0.8 million, driven by Yavne.
Cost of revenue increased to USD 3.3 million from USD 2 million, reflecting a higher fixed cost base post-acquisition.
Gross loss widened to USD 2.4 million from USD 1.3 million; operating loss deepened to USD 4.6 million from USD 3.8 million.
Net profit was USD 1.6 million versus a USD 4.1 million loss, mainly due to a USD 6.4 million bargain-purchase gain.
Cash and cash equivalents were USD 2.7 million at June 30, 2026; operating cash outflow was USD 3.9 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scinai Immunotherapeutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-093738), on August 26, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Scinai posts H1 net profit on $6.4 million bargain-purchase gain, offsetting wider CDMO gross loss

You may also like

Crypto prices